Page last updated: 2024-12-06

nojirimycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nojirimycin is a naturally occurring iminosugar that inhibits α-glucosidase, an enzyme that breaks down carbohydrates. This inhibition leads to reduced glucose absorption and has potential applications in managing diabetes. Nojirimycin also exhibits antiviral activity against various viruses, including HIV and influenza. It is being investigated for its potential therapeutic benefits in treating various diseases, including cancer, inflammatory bowel disease, and Alzheimer's disease.'

nojirimycin: from Streptomyces ficellus; RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65242
CHEMBL ID120638
CHEBI ID28945
SCHEMBL ID140917
MeSH IDM0061539

Synonyms (13)

Synonym
CHEBI:28945 ,
(3r,4s,5r,6r)-6-(hydroxymethyl)piperidine-2,3,4,5-tetrol
5-amino-5-deoxy-d-glucopyranose
C06763
15218-38-9
nojirimycin
CHEMBL120638
bdbm50371136
SCHEMBL140917
BGMYHTUCJVZIRP-GASJEMHNSA-N
Q27103975
d-gluco-piperidinose
gtpl10951

Research Excerpts

Overview

Nojirimycin is a compound in which the oxygen of the ring is replaced with an NH group in the D-glucose structure.

ExcerptReferenceRelevance
"Nojirimycin (NJ) is a compound in which the oxygen of the ring is replaced with an NH group in the D-glucose structure. "( Nojirimycin suppresses inflammation via regulation of NF-κ B signaling pathways.
Chung, YC; Hyun, C-; Hyun, SB, 2020
)
3.44
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
hydroxypiperidine
amino monosaccharideAny amino sugar that is a monosaccharide in which one alcoholic hydroxy group is replaced by an amino group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glucoamylase, intracellular sporulation-specificSaccharomyces cerevisiae S288CKi6.30006.30006.30006.3000AID296103
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID296115Inhibition of Aspergillus wentii beta-D-mannosidase2007Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12
Synthesis and evaluation of amino-threoses in D- and L-series: are five membered ring amino-sugars more potent glycosidase inhibitors than the six membered ones?
AID296106Inhibition of jack bean alpha-D-mannosidase2007Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12
Synthesis and evaluation of amino-threoses in D- and L-series: are five membered ring amino-sugars more potent glycosidase inhibitors than the six membered ones?
AID296105Inhibition of almond beta-D-glucosidase2007Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12
Synthesis and evaluation of amino-threoses in D- and L-series: are five membered ring amino-sugars more potent glycosidase inhibitors than the six membered ones?
AID296103Inhibition of yeast alpha-D-glucosidase2007Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12
Synthesis and evaluation of amino-threoses in D- and L-series: are five membered ring amino-sugars more potent glycosidase inhibitors than the six membered ones?
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (60)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (23.33)18.7374
1990's13 (21.67)18.2507
2000's20 (33.33)29.6817
2010's10 (16.67)24.3611
2020's3 (5.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.73 (24.57)
Research Supply Index4.13 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (8.20%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other56 (91.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]